HSP90AB1 and hyperlipidemia: HSP90AB1 demonstrated good diagnostic accuracy in the nephrolithiasis validation cohort (AUC = 1.000) and in the hyperlipidemia validation cohort (AUC = 0.880) (Fig 9D).